when Cop Gets Shocking Surprise When He Finds Age 5 Boy Behind Wheel of Car Who Had Plans To Go Buy Lamborghini By www.westernjournal.com Published On :: Sat, 09 May 2020 14:47:54 +0000 A 5-year-old Utah boy shocked family and law enforcement when he grabbed the keys to his parents’ car and drove himself through the neighborhood and onto a freeway. Utah Highway Patrol Trooper Rick Morgan spotted the vehicle swerving dangerously on the freeway and initiated a stop, fully expecting to find a driver under the influence… The post Cop Gets Shocking Surprise When He Finds Age 5 Boy Behind Wheel of Car Who Had Plans To Go Buy Lamborghini appeared first on The Western Journal. Full Article Lifestyle Automobile children Emergencies and Accidents police Utah
when What Happens When Police Are Forced to Reform? By feedproxy.google.com Published On :: Fri, 13 Nov 2015 15:45:10 EST The Justice Department has intervened in troubled police departments for 20 years. Are reform efforts working? Full Article
when Sport24.co.za | TOUR TALES | When Polly's boys went 'zero to hero' Down Under By www.sport24.co.za Published On :: Sat, 09 May 2020 09:14:59 +0200 Including a shoulder-brush with a livid Steve Waugh, Rob Houwing remembers witnessing SA's heroic finish to an otherwise stormy 2001/02 Australian tour. Full Article
when 7 Must-Do Hacks for When Your Motivation Dips By feedproxy.google.com Published On :: Mon, 20 Apr 2020 12:21:54 +0000 Do you know that feeling when you are hyped and ready to take on a new challenge? You are taken over by a surge of motivation and excitement and you’ve made a commitment you fully intend to stick to. It sounds familiar, right? Perhaps you declared your intention to dedicate more time to self-care, or […] The post 7 Must-Do Hacks for When Your Motivation Dips appeared first on Dumb Little Man. Full Article Goals Motivation Productivity
when Coronavirus Vaccine: Available For All, or When it's Your Turn? By feedproxy.google.com Published On :: Mon, 04 May 2020 15:39:19 +0000 4 May 2020 Professor David Salisbury CB Associate Fellow, Global Health Programme LinkedIn Despite high-level commitments and pledges to cooperate to ensure equitable global access to a coronavirus vaccine, prospects for fair distribution are uncertain. 2020-05-04-Vaccine-COVID-Brazil Researcher in Brazil working on virus replication in order to develop a vaccine against the coronavirus. Photo by DOUGLAS MAGNO/AFP via Getty Images. When the H1N1 influenza pandemic struck in 2009, some industrialized countries were well prepared. Many countries’ preparedness plans had focused on preparing for an influenza pandemic and based on earlier alerts over the H5N1 ‘bird flu’ virus, countries had made advanced purchase or ‘sleeping’ contracts for vaccine supplies that could be activated as soon as a pandemic was declared. Countries without contracts scrambled to get supplies after those that already had contracts received their vaccine.Following the 2009 pandemic, the European Union (EU) developed plans for joint-purchase vaccine contracts that any member state could join, guaranteeing the same price per dose for everyone. In 2009, low-income countries were unable to get the vaccine until manufacturers agreed to let 10 per cent of their production go to the World Health Organization (WHO).The situation for COVID-19 could be even worse. No country had a sleeping contract in place for a COVID-19 vaccine since nobody had anticipated that the next pandemic would be a coronavirus, not an influenza virus. With around 80 candidate vaccines reported to be in development, choosing the right one will be like playing roulette.These candidates will be whittled down as some will fail at an early stage of development and others will not get to scale-up for manufacturing. All of the world’s major vaccine pharmaceutical companies have said that they will divert resources to manufacture COVID-19 vaccines and, as long as they choose the right candidate for production, they have the expertise and the capacity to produce in huge quantities.From roulette to a horse raceOur game now changes from roulette to a horse race, as the probability of winning is a matter of odds not a random chance. Countries are now able to try to make contracts alone or in purchasing consortia with other states, and with one of the major companies or with multiple companies. This would be like betting on one of the favourites.For example, it has been reported that Oxford University has made an agreement with pharmaceutical company AstraZeneca, with a possibility of 100 million doses being available by the end of 2020. If the vaccine works and those doses materialize, and are all available for the UK, then the UK population requirements will be met in full, and the challenge becomes vaccinating everyone as quickly as possible.Even if half of the doses were reserved for the UK, all those in high-risk or occupational groups could be vaccinated rapidly. However, as each major manufacturer accepts more contracts, the quantity that each country will get diminishes and the time to vaccinate the at-risk population gets longer.At this point, it is not known how manufacturers will respond to requests for vaccine and how they will apportion supplies between different markets. You could bet on an outsider. You study the field and select a biotech that has potential with a good production development programme and a tie-in with a smaller-scale production facility.If other countries do not try to get contracts, you will get your vaccine as fast as manufacturing can be scaled up; but because it is a small manufacturer, your supplies may take a long time. And outsiders do not often win races. You can of course, depending on your resources, cover several runners and try to make multiple contracts. However, you take on the risk that some will fail, and you may have compromised your eventual supply.On April 24, the WHO co-hosted a meeting with the president of France, the president of the European Commission and the Bill & Melinda Gates Foundation. It brought together heads of state and industry leaders who committed to ‘work towards equitable global access based on an unprecedented level of partnership’. They agreed ‘to create a strong unified voice, to build on past experience and to be accountable to the world, to communities and to one another’ for vaccines, testing materials and treatments.They did not, however, say how this will be achieved and the absence of the United States was notable. The EU and its partners are hosting an international pledging conference on May 4 that aims to raise €7.5 billion in initial funding to kick-start global cooperation on vaccines. Co-hosts will be France, Germany, Italy, the United Kingdom, Norway and Saudi Arabia and the priorities will be ‘Test, Treat and Prevent’, with the latter dedicated to vaccines.Despite these expressions of altruism, every government will face the tension between wanting to protect their own populations as quickly as possible and knowing that this will disadvantage poorer countries, where health services are even less able to cope. It will not be a vote winner to offer a share in available vaccine to less-privileged countries.The factories for the biggest vaccine manufacturers are in Europe, the US and India. Will European manufacturers be obliged by the EU to restrict sales first to European countries? Will the US invoke its Defense Production Act and block vaccine exports until there are stocks enough for every American? And will vaccine only be available in India for those who can afford it?The lessons on vaccine availability from the 2009 influenza pandemic are clear: vaccine was not shared on anything like an equitable basis. It remains to be seen if we will do any better in 2020. Full Article
when Coronavirus Vaccine: Available For All, or When it's Your Turn? By feedproxy.google.com Published On :: Mon, 04 May 2020 15:39:19 +0000 4 May 2020 Professor David Salisbury CB Associate Fellow, Global Health Programme LinkedIn Despite high-level commitments and pledges to cooperate to ensure equitable global access to a coronavirus vaccine, prospects for fair distribution are uncertain. 2020-05-04-Vaccine-COVID-Brazil Researcher in Brazil working on virus replication in order to develop a vaccine against the coronavirus. Photo by DOUGLAS MAGNO/AFP via Getty Images. When the H1N1 influenza pandemic struck in 2009, some industrialized countries were well prepared. Many countries’ preparedness plans had focused on preparing for an influenza pandemic and based on earlier alerts over the H5N1 ‘bird flu’ virus, countries had made advanced purchase or ‘sleeping’ contracts for vaccine supplies that could be activated as soon as a pandemic was declared. Countries without contracts scrambled to get supplies after those that already had contracts received their vaccine.Following the 2009 pandemic, the European Union (EU) developed plans for joint-purchase vaccine contracts that any member state could join, guaranteeing the same price per dose for everyone. In 2009, low-income countries were unable to get the vaccine until manufacturers agreed to let 10 per cent of their production go to the World Health Organization (WHO).The situation for COVID-19 could be even worse. No country had a sleeping contract in place for a COVID-19 vaccine since nobody had anticipated that the next pandemic would be a coronavirus, not an influenza virus. With around 80 candidate vaccines reported to be in development, choosing the right one will be like playing roulette.These candidates will be whittled down as some will fail at an early stage of development and others will not get to scale-up for manufacturing. All of the world’s major vaccine pharmaceutical companies have said that they will divert resources to manufacture COVID-19 vaccines and, as long as they choose the right candidate for production, they have the expertise and the capacity to produce in huge quantities.From roulette to a horse raceOur game now changes from roulette to a horse race, as the probability of winning is a matter of odds not a random chance. Countries are now able to try to make contracts alone or in purchasing consortia with other states, and with one of the major companies or with multiple companies. This would be like betting on one of the favourites.For example, it has been reported that Oxford University has made an agreement with pharmaceutical company AstraZeneca, with a possibility of 100 million doses being available by the end of 2020. If the vaccine works and those doses materialize, and are all available for the UK, then the UK population requirements will be met in full, and the challenge becomes vaccinating everyone as quickly as possible.Even if half of the doses were reserved for the UK, all those in high-risk or occupational groups could be vaccinated rapidly. However, as each major manufacturer accepts more contracts, the quantity that each country will get diminishes and the time to vaccinate the at-risk population gets longer.At this point, it is not known how manufacturers will respond to requests for vaccine and how they will apportion supplies between different markets. You could bet on an outsider. You study the field and select a biotech that has potential with a good production development programme and a tie-in with a smaller-scale production facility.If other countries do not try to get contracts, you will get your vaccine as fast as manufacturing can be scaled up; but because it is a small manufacturer, your supplies may take a long time. And outsiders do not often win races. You can of course, depending on your resources, cover several runners and try to make multiple contracts. However, you take on the risk that some will fail, and you may have compromised your eventual supply.On April 24, the WHO co-hosted a meeting with the president of France, the president of the European Commission and the Bill & Melinda Gates Foundation. It brought together heads of state and industry leaders who committed to ‘work towards equitable global access based on an unprecedented level of partnership’. They agreed ‘to create a strong unified voice, to build on past experience and to be accountable to the world, to communities and to one another’ for vaccines, testing materials and treatments.They did not, however, say how this will be achieved and the absence of the United States was notable. The EU and its partners are hosting an international pledging conference on May 4 that aims to raise €7.5 billion in initial funding to kick-start global cooperation on vaccines. Co-hosts will be France, Germany, Italy, the United Kingdom, Norway and Saudi Arabia and the priorities will be ‘Test, Treat and Prevent’, with the latter dedicated to vaccines.Despite these expressions of altruism, every government will face the tension between wanting to protect their own populations as quickly as possible and knowing that this will disadvantage poorer countries, where health services are even less able to cope. It will not be a vote winner to offer a share in available vaccine to less-privileged countries.The factories for the biggest vaccine manufacturers are in Europe, the US and India. Will European manufacturers be obliged by the EU to restrict sales first to European countries? Will the US invoke its Defense Production Act and block vaccine exports until there are stocks enough for every American? And will vaccine only be available in India for those who can afford it?The lessons on vaccine availability from the 2009 influenza pandemic are clear: vaccine was not shared on anything like an equitable basis. It remains to be seen if we will do any better in 2020. Full Article
when Coronavirus Vaccine: Available For All, or When it's Your Turn? By feedproxy.google.com Published On :: Mon, 04 May 2020 15:39:19 +0000 4 May 2020 Professor David Salisbury CB Associate Fellow, Global Health Programme LinkedIn Despite high-level commitments and pledges to cooperate to ensure equitable global access to a coronavirus vaccine, prospects for fair distribution are uncertain. 2020-05-04-Vaccine-COVID-Brazil Researcher in Brazil working on virus replication in order to develop a vaccine against the coronavirus. Photo by DOUGLAS MAGNO/AFP via Getty Images. When the H1N1 influenza pandemic struck in 2009, some industrialized countries were well prepared. Many countries’ preparedness plans had focused on preparing for an influenza pandemic and based on earlier alerts over the H5N1 ‘bird flu’ virus, countries had made advanced purchase or ‘sleeping’ contracts for vaccine supplies that could be activated as soon as a pandemic was declared. Countries without contracts scrambled to get supplies after those that already had contracts received their vaccine.Following the 2009 pandemic, the European Union (EU) developed plans for joint-purchase vaccine contracts that any member state could join, guaranteeing the same price per dose for everyone. In 2009, low-income countries were unable to get the vaccine until manufacturers agreed to let 10 per cent of their production go to the World Health Organization (WHO).The situation for COVID-19 could be even worse. No country had a sleeping contract in place for a COVID-19 vaccine since nobody had anticipated that the next pandemic would be a coronavirus, not an influenza virus. With around 80 candidate vaccines reported to be in development, choosing the right one will be like playing roulette.These candidates will be whittled down as some will fail at an early stage of development and others will not get to scale-up for manufacturing. All of the world’s major vaccine pharmaceutical companies have said that they will divert resources to manufacture COVID-19 vaccines and, as long as they choose the right candidate for production, they have the expertise and the capacity to produce in huge quantities.From roulette to a horse raceOur game now changes from roulette to a horse race, as the probability of winning is a matter of odds not a random chance. Countries are now able to try to make contracts alone or in purchasing consortia with other states, and with one of the major companies or with multiple companies. This would be like betting on one of the favourites.For example, it has been reported that Oxford University has made an agreement with pharmaceutical company AstraZeneca, with a possibility of 100 million doses being available by the end of 2020. If the vaccine works and those doses materialize, and are all available for the UK, then the UK population requirements will be met in full, and the challenge becomes vaccinating everyone as quickly as possible.Even if half of the doses were reserved for the UK, all those in high-risk or occupational groups could be vaccinated rapidly. However, as each major manufacturer accepts more contracts, the quantity that each country will get diminishes and the time to vaccinate the at-risk population gets longer.At this point, it is not known how manufacturers will respond to requests for vaccine and how they will apportion supplies between different markets. You could bet on an outsider. You study the field and select a biotech that has potential with a good production development programme and a tie-in with a smaller-scale production facility.If other countries do not try to get contracts, you will get your vaccine as fast as manufacturing can be scaled up; but because it is a small manufacturer, your supplies may take a long time. And outsiders do not often win races. You can of course, depending on your resources, cover several runners and try to make multiple contracts. However, you take on the risk that some will fail, and you may have compromised your eventual supply.On April 24, the WHO co-hosted a meeting with the president of France, the president of the European Commission and the Bill & Melinda Gates Foundation. It brought together heads of state and industry leaders who committed to ‘work towards equitable global access based on an unprecedented level of partnership’. They agreed ‘to create a strong unified voice, to build on past experience and to be accountable to the world, to communities and to one another’ for vaccines, testing materials and treatments.They did not, however, say how this will be achieved and the absence of the United States was notable. The EU and its partners are hosting an international pledging conference on May 4 that aims to raise €7.5 billion in initial funding to kick-start global cooperation on vaccines. Co-hosts will be France, Germany, Italy, the United Kingdom, Norway and Saudi Arabia and the priorities will be ‘Test, Treat and Prevent’, with the latter dedicated to vaccines.Despite these expressions of altruism, every government will face the tension between wanting to protect their own populations as quickly as possible and knowing that this will disadvantage poorer countries, where health services are even less able to cope. It will not be a vote winner to offer a share in available vaccine to less-privileged countries.The factories for the biggest vaccine manufacturers are in Europe, the US and India. Will European manufacturers be obliged by the EU to restrict sales first to European countries? Will the US invoke its Defense Production Act and block vaccine exports until there are stocks enough for every American? And will vaccine only be available in India for those who can afford it?The lessons on vaccine availability from the 2009 influenza pandemic are clear: vaccine was not shared on anything like an equitable basis. It remains to be seen if we will do any better in 2020. Full Article
when When Your Passion Works Against You By www8.gsb.columbia.edu Published On :: Wed, 06 May 2020 17:02:52 +0000 Strategy Tuesday, April 28, 2020 - 13:00 Full Article
when CBD News: It is a pleasure to join you here in Kuala Lumpur for the fourth session of the IPBES Plenary. We come together for a very exciting moment in the history of IPBES, when the Plenary will be presented with the first two assessments for its accepta By www.cbd.int Published On :: Mon, 22 Feb 2016 00:00:00 GMT Full Article
when Continuous Insulin Infusion: When, Where, and How? By spectrum.diabetesjournals.org Published On :: 2014-08-01 Janet L. KellyAug 1, 2014; 27:218-223Pharmacy and Therapeutics Full Article
when SAS Notes for SAS®9 - 40995: The SAS Universal Viewer converts null values into zeros when you save an XPT file as an XML or CSV file By feedproxy.google.com Published On :: Thu, 7 May 2020 10:31:41 EST The SAS Universal Viewer displays null values appropriately as blanks for XPT files. However, when you select Table ? Save As and save an XPT file as either an XML or CSV file, the SAS Universal Viewer con Full Article SASUNIVIEWER+SAS+Universal+Viewer
when Police stop fewer black drivers at night when a 'veil of darkness' obscures their race By www.eurekalert.org Published On :: Wed, 06 May 2020 00:00:00 EDT (Stanford School of Engineering) After analyzing 95 million traffic stop records, filed by officers with 21 state patrol agencies and 35 municipal police forces from 2011 to 2018, a Stanford-led research team concluded that 'police stops and search decisions suffer from persistent racial bias.' Full Article
when Glycemic Control and Hemoglobinopathy: When A1C May Not Be Reliable By spectrum.diabetesjournals.org Published On :: 2008-01-01 Arlene SmaldoneJan 1, 2008; 21:46-49Evidence-Based Clinical Decision Making Full Article
when Governments Should Be Transparent When Planning to End Lockdowns By www8.gsb.columbia.edu Published On :: Thu, 07 May 2020 00:00:00 -0400 Businesses will benefit from clear policy guidance from lawmakers Full Article
when Geneva Launch: Protecting Civilians — When is ‘Incidental Harm’ Excessive? By feedproxy.google.com Published On :: Tue, 02 Oct 2018 13:45:01 +0000 Research Event 14 December 2018 - 10:00am to 11:30am Graduate Institute | Chemin Eugène-Rigot 2 | 1202 Geneva | Switzerland Event participants Emanuela-Chiara Gillard, Associate Fellow, International Law Programme, Chatham HouseEzequiel Heffes, Thematic Legal Adviser, Geneva CallSigrid Redse Johansen, Judge Advocate General, The Norwegian Armed ForcesChair: Elizabeth Wilmshurst, Distinguished Fellow, Chatham HouseFurther speakers to be announced. PLEASE NOTE THIS EVENT IS BEING HELD IN GENEVA.There have been large numbers of civilian deaths in the armed conflicts in Yemen and Syria. Is international humanitarian law being ignored? This meeting coincides with the launch of a Chatham House research paper on the incidental harm side of the proportionality assessment which belligerents are legally required to make. The panel at the meeting will consider the types of harm that fall within the scope of proportionality assessments, what constitutes ‘excessive’ harm and measures that belligerents can take to give effect to the rule on proportionality.This event will be followed by a reception. Department/project International Law Programme Chanu Peiris Programme Manager, International Law +44 (0)20 7314 3686 Email Full Article
when London Launch: Protecting Civilians — When is ‘Incidental Harm’ Excessive? By feedproxy.google.com Published On :: Tue, 06 Nov 2018 18:25:01 +0000 Research Event 14 January 2019 - 5:30pm to 7:00pm Chatham House, London Event participants Emanuela-Chiara Gillard, Associate Fellow, International Law Programme, Chatham HouseEzequiel Heffes, Thematic Legal Adviser, Geneva CallSigrid Redse Johansen, Judge Advocate General, Norwegian Armed ForcesAndrew Murdoch, Legal Director, UK Foreign & Commonwealth OfficeChair: Elizabeth Wilmshurst, Distinguished Fellow, International Law Programme, Chatham House There have been large numbers of civilian deaths in the armed conflicts in Yemen and Syria. Is international humanitarian law being ignored?This meeting marks the London launch of a Chatham House research paper on the incidental harm side of the proportionality assessment which belligerents are legally required to make. The panel at the meeting will consider the types of harm that fall within the scope of proportionality assessments, what constitutes ‘excessive’ harm and measures that belligerents can take to give effect to the rule on proportionality.This event will be followed by a reception. Department/project International Law Programme, Rights, Accountability and Justice Chanu Peiris Programme Manager, International Law +44 (0)20 7314 3686 Email Full Article
when Can the government really protect your privacy when it 'de-identifies' public data? By www.smh.com.au Published On :: Mon, 05 Dec 2016 12:45:00 GMT We don't really know to how to use big data and protect personal information at the same time. Full Article
when Coronavirus Vaccine: Available For All, or When it's Your Turn? By feedproxy.google.com Published On :: Mon, 04 May 2020 15:39:19 +0000 4 May 2020 Professor David Salisbury CB Associate Fellow, Global Health Programme LinkedIn Despite high-level commitments and pledges to cooperate to ensure equitable global access to a coronavirus vaccine, prospects for fair distribution are uncertain. 2020-05-04-Vaccine-COVID-Brazil Researcher in Brazil working on virus replication in order to develop a vaccine against the coronavirus. Photo by DOUGLAS MAGNO/AFP via Getty Images. When the H1N1 influenza pandemic struck in 2009, some industrialized countries were well prepared. Many countries’ preparedness plans had focused on preparing for an influenza pandemic and based on earlier alerts over the H5N1 ‘bird flu’ virus, countries had made advanced purchase or ‘sleeping’ contracts for vaccine supplies that could be activated as soon as a pandemic was declared. Countries without contracts scrambled to get supplies after those that already had contracts received their vaccine.Following the 2009 pandemic, the European Union (EU) developed plans for joint-purchase vaccine contracts that any member state could join, guaranteeing the same price per dose for everyone. In 2009, low-income countries were unable to get the vaccine until manufacturers agreed to let 10 per cent of their production go to the World Health Organization (WHO).The situation for COVID-19 could be even worse. No country had a sleeping contract in place for a COVID-19 vaccine since nobody had anticipated that the next pandemic would be a coronavirus, not an influenza virus. With around 80 candidate vaccines reported to be in development, choosing the right one will be like playing roulette.These candidates will be whittled down as some will fail at an early stage of development and others will not get to scale-up for manufacturing. All of the world’s major vaccine pharmaceutical companies have said that they will divert resources to manufacture COVID-19 vaccines and, as long as they choose the right candidate for production, they have the expertise and the capacity to produce in huge quantities.From roulette to a horse raceOur game now changes from roulette to a horse race, as the probability of winning is a matter of odds not a random chance. Countries are now able to try to make contracts alone or in purchasing consortia with other states, and with one of the major companies or with multiple companies. This would be like betting on one of the favourites.For example, it has been reported that Oxford University has made an agreement with pharmaceutical company AstraZeneca, with a possibility of 100 million doses being available by the end of 2020. If the vaccine works and those doses materialize, and are all available for the UK, then the UK population requirements will be met in full, and the challenge becomes vaccinating everyone as quickly as possible.Even if half of the doses were reserved for the UK, all those in high-risk or occupational groups could be vaccinated rapidly. However, as each major manufacturer accepts more contracts, the quantity that each country will get diminishes and the time to vaccinate the at-risk population gets longer.At this point, it is not known how manufacturers will respond to requests for vaccine and how they will apportion supplies between different markets. You could bet on an outsider. You study the field and select a biotech that has potential with a good production development programme and a tie-in with a smaller-scale production facility.If other countries do not try to get contracts, you will get your vaccine as fast as manufacturing can be scaled up; but because it is a small manufacturer, your supplies may take a long time. And outsiders do not often win races. You can of course, depending on your resources, cover several runners and try to make multiple contracts. However, you take on the risk that some will fail, and you may have compromised your eventual supply.On April 24, the WHO co-hosted a meeting with the president of France, the president of the European Commission and the Bill & Melinda Gates Foundation. It brought together heads of state and industry leaders who committed to ‘work towards equitable global access based on an unprecedented level of partnership’. They agreed ‘to create a strong unified voice, to build on past experience and to be accountable to the world, to communities and to one another’ for vaccines, testing materials and treatments.They did not, however, say how this will be achieved and the absence of the United States was notable. The EU and its partners are hosting an international pledging conference on May 4 that aims to raise €7.5 billion in initial funding to kick-start global cooperation on vaccines. Co-hosts will be France, Germany, Italy, the United Kingdom, Norway and Saudi Arabia and the priorities will be ‘Test, Treat and Prevent’, with the latter dedicated to vaccines.Despite these expressions of altruism, every government will face the tension between wanting to protect their own populations as quickly as possible and knowing that this will disadvantage poorer countries, where health services are even less able to cope. It will not be a vote winner to offer a share in available vaccine to less-privileged countries.The factories for the biggest vaccine manufacturers are in Europe, the US and India. Will European manufacturers be obliged by the EU to restrict sales first to European countries? Will the US invoke its Defense Production Act and block vaccine exports until there are stocks enough for every American? And will vaccine only be available in India for those who can afford it?The lessons on vaccine availability from the 2009 influenza pandemic are clear: vaccine was not shared on anything like an equitable basis. It remains to be seen if we will do any better in 2020. Full Article
when Problem Notes for SAS®9 - 65852: The PANEL procedure produces incorrect results for certain models when the NOINT and RANONE options are specified By feedproxy.google.com Published On :: Fri, 8 May 2020 13:34:29 EST The estimation results might be incorrect in PROC PANEL when the RANONE and NOINT options are specified in the MODEL statement. Full Article ETS+SAS/ETS
when Problem Notes for SAS®9 - 65940: You might receive "ERROR: PI Point not found" when you query a PI tag name that contains a special character such as an ampersand (&) By feedproxy.google.com Published On :: Fri, 8 May 2020 11:20:36 EST When you query a PI tag name or element that contains a special character, such as an ampersand (&), you might receive the following error: Full Article OSISOFT+SAS/ACCESS+Interface+to+the+PI+S
when Problem Notes for SAS®9 - 65939: "ERROR: Unable to transcode data to/from UCS-2 encoding" occurs when you run an SQL query using SAS/ACCESS Interface to ODBC on SAS 9.4M5 with UTF-8 By feedproxy.google.com Published On :: Fri, 8 May 2020 11:20:02 EST When you run an SQL query using SAS/ACCESS Interface to ODBC under the following conditions, you might receive an error: You run SAS 9.4M5 (TS1M5) or SAS 9.4M6 (TS1M6) i Full Article ODBC+SAS/ACCESS+Interface+to+ODBC
when Problem Notes for SAS®9 - 35066: When a bulk-loading process fails with "SQL*Loader 2026" error, error message appears as a warning in the SAS log By feedproxy.google.com Published On :: Thu, 7 May 2020 17:15:19 EST If a bulk-loading process fails when you use SAS with SAS/ACCESS Interface to Oracle, you will receive the warning: "WARNING: All or some rows were rejected/discarded.: The actual error is "SQL*Loader-2026: The load was aborted because SQL Full Article ORACLE+SAS/ACCESS+Interface+to+Oracle
when Problem Notes for SAS®9 - 65834: PROC METADATA returns various errors when the input contains certain multi-byte characters By feedproxy.google.com Published On :: Thu, 7 May 2020 17:12:13 EST The METADATA procedure might return an error similar to one of the following: ERROR: Missing root element definition. Full Article BASE+Base+SAS
when Problem Notes for SAS®9 - 65899: "ERROR: ORACLE disconnect error: ORA-03135" occurs when SAS disconnects from the Oracle database server By feedproxy.google.com Published On :: Thu, 7 May 2020 08:04:08 EST When you run 32-bit SAS on Windows and disconnect from the Oracle database server, you might see the error: "ERROR: ORACLE disconnect error: ORA-03135: connection lost contact." Full Article ORACLE+SAS/ACCESS+Interface+to+Oracle
when Problem Notes for SAS®9 - 65295: The order of columns is not maintained when you select columns for output in the Business Rules transformation By feedproxy.google.com Published On :: Wed, 6 May 2020 10:01:07 EST In SAS Data Integration Studio, the columns that you select to include in the target table in a Business Rules transformation appear in the Selected columns area in a random order. Th Full Article DATABUILDER+SAS+Data+Integration+Studio
when Problem Notes for SAS®9 - 65903: You see a "java.lang.IllegalArgumentException" error in the log file when you use the IFRS9_Cycle workflow template in SAS Solution for IFRS 9 By feedproxy.google.com Published On :: Fri, 1 May 2020 18:01:29 EST The problem occurs on a content release on the SAS Risk Governance Framework. Full Article RGPBNDL+SAS+Risk+Governance+Framework
when Problem Notes for SAS®9 - 65872: You see a "java.lang.IllegalArgumentException" error in the log file when you use the CECL_Cycle workflow template in SAS Solution for CECL By feedproxy.google.com Published On :: Fri, 1 May 2020 16:53:01 EST The problem occurs on a content release on the SAS Risk Governance Framework. Full Article RGPBNDL+SAS+Risk+Governance+Framework
when Problem Notes for SAS®9 - 65904: SAS Federation Server stops responding when you run queries against X_OBJECT_PRIVILEGES in SYSCAT and the queries run for hours By feedproxy.google.com Published On :: Fri, 1 May 2020 14:48:24 EST The select * from "SYSCAT"."SYSCAT"."X_EFFECTIVE_OBJECT_PRIVILEGES" query runs for hours. In this scenario, SAS Federation Server stops responding, making it unavailable for use. Restarting SAS Federation Server solves t Full Article DFFEDSVR+SAS+Federation+Server
when Problem Notes for SAS®9 - 65682: Running FedSQL with an Oracle table is slow, even when you use a LIMIT clause By feedproxy.google.com Published On :: Fri, 1 May 2020 14:43:59 EST When you query an Oracle table and use the LIMIT clause using either SAS Federation Server or FedSQL, a row limit is not passed to the database. In this scenario, a Full Article DFFEDSVR+SAS+Federation+Server
when Problem Notes for SAS®9 - 65898: A misleading SASTRACE message appears in the log when you insert a row into an Oracle table using SAS/ACCESS Interface to Oracle with DBIDIRECTEXEC By feedproxy.google.com Published On :: Thu, 30 Apr 2020 13:52:24 EST When you add one row to an Oracle table using DBIDIRECTEXEC, you see the following misleading trace message: "ORACLE: 4294967296 rows inserted/updated/deleted." You should see something similar to the following: "ORACLE: 1 rows inserte Full Article ORACLE+SAS/ACCESS+Interface+to+Oracle
when Problem Notes for SAS®9 - 65909: SAS Visual Analytics Designer 7.5 responds slowly when you edit large or complex reports By feedproxy.google.com Published On :: Thu, 30 Apr 2020 13:26:35 EST If your SAS Visual Analytics report contains many sections and objects, you might encounter performance problems when you are editing the report. A hot fix is planned for this issue. Full Article VISANLYTBNDL+SAS+Visual+Analytics
when Problem Notes for SAS®9 - 65893: Custom sorts are sorted incorrectly when they are used in a hierarchy in SAS Visual Analytics Designer By feedproxy.google.com Published On :: Wed, 29 Apr 2020 12:29:05 EST A custom sort might be sorted incorrectly when the data item is used in a custom category, which is then used in a hierarchy. The issue can occur in the following scenario: Full Article VISANLYTBNDL+SAS+Visual+Analytics
when Problem Notes for SAS®9 - 65883: SAS Workflow Studio returns a "cannot load" error when you try to open the CECL_Cycle_AFS workflow template for SAS Solution for CECL By feedproxy.google.com Published On :: Mon, 27 Apr 2020 16:10:54 EST You might see the following error in SAS Workflow Studio when you try to open the CECL_Cycle_AFS workflow template that is shipped with SAS Solution for CECL: Full Article RGPBNDL+SAS+Risk+Governance+Framework
when Nicotine and Insulin Resistance: When the Smoke Clears By diabetes.diabetesjournals.org Published On :: 2012-12-01 Mandeep BajajDec 1, 2012; 61:3078-3080Commentary Full Article
when Re: David Oliver: Let’s not forget care homes when covid-19 is over - What should we expect from care homes after Covid-19? By feeds.bmj.com Published On :: Friday, May 8, 2020 - 07:56 Full Article
when The dynamics of dissent: when actions are louder than words By feedproxy.google.com Published On :: Thu, 02 May 2019 10:01:15 +0000 2 May 2019 , Volume 95, Number 3 In the latest issue a collection of articles explore how international norms are increasingly contested by both state and non-state actors. Read online Anette Stimmer and Lea Wisken A profusion of international norms influences state behaviour. Ambiguities and tensions in the normative framework can give rise to contestation. While research on norm contestation has focused on open debates about norms, we identify a second type of norm contestation where norms are contested through particular forms of implementation. We therefore distinguish between contestation through words and actions, that is, discursive and behavioural contestation. Discursive contestation involves debates about the meaning and/or (relative) importance of norms. Behavioural contestation, by contrast, eschews such debates. Instead, different norm understandings become apparent in the different ways in which actors shape the implementation of norms. Despite being a potentially powerful mechanism of challenging and changing norms, behavioural contestation has fallen outside the purview of the literature in part because it frequently remains below the radar. The two forms of contestation overlap when the practices of behavioural contestation are brought to the attention of and discussed by the international community. Thus, discursive and behavioural contestation are not mutually exclusive but can happen at the same time, sequentially or independently of each other. This introduction to a special section of the May 2019 issue of International Affairs, on ‘The dynamics of dissent’, develops the concept of behavioural contestation and outlines triggers and effects of this hitherto under-researched expression of dissent. Full Article
when Diabetes remission - "treating blood glucose, when the disease process is to do with body fat" By feeds.bmj.com Published On :: Fri, 22 Sep 2017 15:25:47 +0000 In the UK - type 2 diabetes now affects between 5-10% of the population - and accounts for around 10% of our total NHS budget. For the individuals affected, treatments are effective at helping control glucose levels - however, the sequela associated with the disease - vascular problems, and a life expectancy that’s 6 years shorter - are still an... Full Article
when When an investigative journalist calls By feeds.bmj.com Published On :: Fri, 22 Jun 2018 17:11:23 +0000 At Evidence Live this year, the focus of the conference was on communication of evidence - both academically, and to the public. And part of that is the role that investigative journalism has to play in that. At the BMJ we’ve used investigative journalistic techniques to try and expose wrong doing on the part of government and industry - always... Full Article
when When Disaster Strikes: Responding to Migrants Caught in Crises By www.migrationpolicy.org Published On :: Wed, 05 Sep 2018 12:08:35 -0400 Migrants displaced by crisis do not benefit from international protection the way that refugees do. This article examines the experiences of labor migrants amid manmade and natural disasters in the Central African Republic, Côte d’Ivoire, Lebanon, Libya, South Africa, and Thailand, as well as stakeholder responses. Research demonstrates the agency and resilience of migrants, who develop flexible solutions in the face of crisis. Full Article
when ‘It’s very rewarding when dentists can treat veterans’ By www.ada.org Published On :: Mon, 27 Jan 2020 13:45:00 -0600 “Our nation’s veterans deserve the best.” Those were the words of ADA President Chad P. Gehani following his Jan. 7 visit to the Orlando VA Healthcare System’s dental clinic. Full Article
when ADA releases interim guidance on minimizing COVID-19 transmission risk when treating dental emergencies By www.ada.org Published On :: Wed, 01 Apr 2020 20:20:00 -0500 The American Dental Association has released interim guidance for dentists on how to minimize the risk of COVID-19 transmission before, during and after treating dental emergencies. Full Article
when Two new dental benefit guides address common hurdles anticipated when reopening practices By www.ada.org Published On :: Mon, 04 May 2020 11:26:00 -0500 In the face of economic challenges, the ADA has released two online guides relating to third-party payment programs available at ADA.org/virus that are intended to help smooth the path of reopening practices: Handling Contract Negotiations and Handling Eligibility Verification Full Article
when How to Stop Waiting for ‘When Coronavirus Ends’ By psychcentral.com Published On :: Tue, 05 May 2020 10:30:56 +0000 How many times have you thought, “When coronavirus ends, I will ______” — as if you’re putting off everything (or at least the things you most love) until then? They... Full Article Creativity Mindfulness Motivation and Inspiration Self-Help coronavirus COVID-19 pandemic Present Moment
when [ Investing ] Open Question : What does an investor do when his stock notifies him...the company confirms a record date for a forward two for one stock split? By answers.yahoo.com Published On :: Sat, 09 May 2020 17:16:31 +0000 Full Article
when [ Religion & Spirituality ] Open Question : Does God love it when you call him Big Poppa? By answers.yahoo.com Published On :: Sat, 09 May 2020 17:17:49 +0000 Full Article
when [ Politics ] Open Question : Libtards, don't get your panties in a bunch when those two Georgia 2nd amendment warriors are found innocent of killing that black guy? By answers.yahoo.com Published On :: Sat, 09 May 2020 17:20:10 +0000 He shouldn't have fought back when the guy pointed the shot gun at him Full Article
when [ Politics ] Open Question : When will the democrats be arrested for being trators to SAmerica by conspiring with chine to make trump looik bad? By answers.yahoo.com Published On :: Sat, 09 May 2020 17:23:29 +0000 Full Article
when When the Dust Settles: Migration Policy after Brexit By www.migrationpolicy.org Published On :: Sun, 26 Jun 2016 15:16:18 -0400 While the political and economic ramifications of the UK vote to quit the European Union hit with full force within hours, it will take far more time to sort out what Brexit means for migration policy. In the short term, the rights of EU nationals living in Britain are the most pressing, with border-control negotiations and future immigration levels also high on the agenda. Against a backdrop of deep public skepticism, this commentary suggests the next government should underpromise and overdeliver. Full Article
when When Staying Cool Seems Better Than Being Bad By www.washingtonpost.com Published On :: Mon, 07 Aug 2006 00:00:00 EDT So the bad news is that it is hot and sticky and muggy. Your skin makes tearing sounds when you get up from a plastic chair. On the Metro, you start to tell people apart by how they smell. Full Article Nation When Staying Cool Seems Better Than Being Bad
when When Seeing Is Disbelieving By www.washingtonpost.com Published On :: Mon, 30 Apr 2007 00:00:00 EDT Four years ago tomorrow, President Bush landed on the USS Abraham Lincoln and dramatically strode onto the deck in a flight suit, a crash helmet tucked under one arm. Even without the giant banner that hung from the ship's tower, the president's message about the progress of the war in Iraq was u... Full Article Opinions When Seeing Is Disbelieving